MD Pediatrix Medical Group, Inc.
Data as of close
Healthcare · Services-Hospitals
Pediatrix Medical Group, Inc. (MD) is a healthcare company in the Services-Hospitals industry, with a market capitalization of $2.6 billion. Shares last traded at $32.81, near their 52-week high. Over the past year the stock is up 55.7%. MD trades at a price-to-earnings ratio of 17.08, below the Healthcare median of 27.34. Net profit margin is 7.7%, above the peer median of -0.5%. Revenue declined 4.9% year over year.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-09-30. Source: SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q3 2026 | $0.59 | 2026-10-29 |
| Q2 2026 | $0.49 | 2026-08-04 |
| Q1 2026 | $0.36 | 2026-05-05 |
| Q4 2025 (derived) | $0.40 | 2026-02-19 |
| FY 2025 | $1.94 | 2026-02-19 |
| Q3 2025 | $0.84 | 2025-11-03 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Healthcare peers
MD vs 14 sector peers (Healthcare), by market cap. Data as of close
| LLY | Lilly (Eli) | $1.33T | 48.37 | 15.43 | 31.9% | +0.62% |
| JNJ | Johnson & Johnson | $665.2B | 41.33 | 6.70 | 16.2% | +3.82% |
| ONC | Beone Medicines Ltd. | $558.0B | 850.93 | 91.04 | 10.7% | +6.36% |
| ABBV | AbbVie | $521.3B | 50.40 | 7.90 | 15.7% | +3.16% |
| MRK | Merck | $370.7B | 151.12 | 5.50 | 3.6% | +3.93% |
| TMO | Thermo Fisher Scientific | $261.7B | 37.00 | 5.53 | 14.9% | +1.12% |
| AMGN | Amgen | $258.7B | 27.55 | 6.65 | 24.1% | +3.81% |
| GILD | Gilead Sciences | $216.4B | — | 6.98 | -12.5% | +4.15% |
| ABT | Abbott Laboratories | $200.2B | 42.58 | 4.15 | 9.7% | +5.61% |
| KLAC | KLA Corporation | $195.3B | 37.14 | 13.46 | 36.2% | -4.02% |
| PFE | Pfizer | $175.5B | 43.52 | 2.76 | 6.3% | +2.70% |
| ISRG | Intuitive Surgical | $167.2B | 56.53 | 14.44 | 25.5% | +9.43% |
| DHR | Danaher Corporation | $165.3B | 38.16 | 6.45 | 16.9% | +2.09% |
| VRTX | Vertex Pharmaceuticals | $139.2B | 35.01 | 10.75 | 30.7% | +3.37% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.